Vericel Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
19.00
28,796.00
51,168.00
54,383.00
63,924.00
90,857
Cost of Goods Sold (COGS) incl. D&A
493.00
14,793.00
26,470.00
28,307.00
30,354.00
32,160
Gross Income
474.00
14,003.00
24,698.00
26,076.00
33,570.00
58,697
SG&A Expense
20,082.00
34,537.00
41,369.00
42,383.00
48,554.00
62,606
EBIT
20,556.00
20,534.00
16,671.00
16,307.00
14,984.00
3,909
Unusual Expense
4,929.00
3,027.00
324.00
2,938.00
1,117.00
3,362
Non Operating Income/Expense
-
3,623.00
20.00
15.00
92.00
31
Interest Expense
11.00
6.00
9.00
314.00
1,107.00
1,732
Pretax Income
15,622.00
19,920.00
16,340.00
19,566.00
17,286.00
8,137
Consolidated Net Income
20,974.00
19,920.00
16,340.00
19,566.00
17,286.00
8,137
Net Income
20,974.00
19,920.00
16,340.00
19,566.00
17,286.00
8,137
Net Income After Extraordinaries
20,974.00
19,920.00
16,340.00
19,566.00
17,286.00
8,137
Net Income Available to Common
20,974.00
25,925.00
23,076.00
27,145.00
17,286.00
8,137
EPS (Basic)
6.95
2.23
0.97
1.18
0.52
0.20
Basic Shares Outstanding
3,016.00
11,642.00
23,760.00
23,093.00
33,355.00
40,242
EPS (Diluted)
6.95
2.23
0.97
1.18
0.52
0.20
Diluted Shares Outstanding
3,016.00
11,642.00
23,760.00
23,093.00
33,355.00
40,242
EBITDA
20,067.00
19,782.00
15,079.00
14,421.00
13,372.00
2,483
Non-Operating Interest Income
16.00
24.00
36.00
8.00
14.00
897
Other After Tax Income (Expense)
5,352.00
-
-
-
-
-
Preferred Dividends
-
6,005.00
6,736.00
7,579.00
-
-

About Vericel

View Profile
Address
64 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.vcel.com
Updated 07/08/2019
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee.